Aernoud Fiolet

89 Colchicine in Stable Coronary Artery Disease 53. Tufan A, Dede DS, Cavus S, Altintas ND, Iskit AB, Topeli A. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother. 2006;40(7-8):1466-1469. doi:aph.1H064 54. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18(2):264- 269. 55. Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV. Colchicine clearance is impaired in alcoholic cirrhosis. Hepatology. 1991;14(6):1013-1015. 56. Ben-Chetrit E, Levy M. Colchicine: 1998 update. In: Seminars in Arthritis and Rheumatism. Vol 28. Elsevier; 1998:48-59. 57. Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K. Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure. J Nephrol. 2006;19(4):515. 58. Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E. Acute colchicine intoxication--possible role of erythromycin administration. J Rheumatol. 1992;19(3):494-496. 59. Hung IF, Wu AK, Cheng VC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis. 2005;41(3):291-300. doi:CID36109 60. Schenone AL, Menon V. Colchicine in Pericardial Disease: from the Underlying Biology and Clinical Benefits to the Drug-Drug Interactions in Cardiovascular Medicine. Curr Cardiol Rep. 2018;20(8):62. 61. Ayubi E, Safiri S. Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin; Methodologic Issues. Am J Med. 2017;130(10):e467. 62. Wason S, Digiacinto JL, Davis MW. Clinically Significant Pharmacokinetic Interaction Between Colchicine and Ritonavir in Healthy Volunteers. Clin Med InsightsTherapeutics. 2013;5:25. 63. Frydrychowicz C, Pasieka B, Pierer M, Mueller W, Petros S, Weidhase L. Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report. J Med Case Rep. 2017;11(1):8. 64. Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468-e495. 65. Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004;30(6):799-802. 66. Alayli G, Cengiz K, Canturk F, Durmus D, Akyol Y, Menekse EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39(7-8):1358-1361. doi:aph.1E593 67. Terkeltaub RA, Furst DE, DiGiacinto JL, Kook KA, Davis MW. Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226-2237. 68. Minetti EE, Minetti L. Multiple organ failure in a kidney transplant patient receiving both colchicine and cyclosporine. J Nephrol. 2003;16(3):421-426.